Related Experiment Video
Updated: Jul 16, 2026
08:34
Isolation of Atrial Myocytes from Adult Mice
Published on: July 25, 2019
Bradycardia can induce increased serum natriuretic peptide-level
International Journal of Cardiology
|March 3, 2007
Summary
Beta-blocker medication caused a slow heart rhythm (sinus arrest) in an elderly woman, leading to elevated NT-proBNP levels. Stopping the drug restored normal heart rhythm and lowered NT-proBNP, suggesting a rare condition.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Beta-blockers are commonly prescribed antihypertensive medications.
- Sinus arrest is a rare but serious cardiac arrhythmia.
Observation:
- An elderly woman on beta-blocker therapy developed sinus arrest with a junctional escape rhythm.
- Despite bradycardia, no overt heart failure signs were present.
- Elevated amino-terminal pro-brain natriuretic peptide (NT-proBNP) levels were detected.
Findings:
- Cessation of beta-blocker therapy led to the restoration of normal sinus rhythm.
- A rapid decrease in NT-proBNP serum levels was observed after drug withdrawal.
- The case highlights a potential link between beta-blocker-induced bradycardia and elevated NT-proBNP.
Implications:
- This case suggests bradycardia-related cardiomyopathy as a rare complication of beta-blocker therapy.
- Monitoring NT-proBNP may be valuable in patients with unexplained bradycardia on beta-blockers.
- Further research is warranted to understand this rare phenomenon.
Related Concept Videos
01:14Decreased pulse rate
Bradycardia is a medical condition in which the heart rate is slower than normal. It occurs when the heart's natural pacemaker, the sinus node, generates slower electrical impulses than the standard rhythm. In adults, bradycardia is diagnosed when the pulse rate falls below 60 beats per minute, indicating a deviation from the normal heart rate range.
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with bradycardia...
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with bradycardia...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:17Hormonal Regulation of Blood Pressure
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...